Home › Glioma › New York › New York City
Glioma clinical trials in New York City, NY
25 studies for Glioma are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RecruitingPhase 1/2
- Research Site, New York
- Research Site, New York
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RecruitingPhase 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RecruitingPhase 2
- Columbia University Irving Medical Center, New York
A Study of Mirdametinib in People With Central Nervous System Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Glioma Developmental and HyperActive Ras Tumor (DHART) Board
RecruitingObservational study
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- and 1 more
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
RecruitingPhase 1
- New York University, New York
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RecruitingPhase 4
- New York Presbyterian Hospital-Columbia University Medical Center, New York
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
RecruitingPhase 1
- NYU Langone Health, New York
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Recruiting
- NYU Langone Health, New York
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Chronic CED of TPT for Recurrent Malignant Glioma
RecruitingPhase 1
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York
A Study of 177Lu-PSMA-617 in People With Gliomas
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RecruitingPhase 3
- Lenox Hill Brain Tumor Center, New York
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Recruiting
- Lenox Hill Brain Tumor Center, New York
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Recruiting
- Lenox Hill Brain Tumor Center, New York
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RecruitingPhase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Columbia University Medical Center, New York
- Memorial Slone Kettering Cancer Center, New York
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
RecruitingPhase 1
- Memorial Sloan Kettering, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RecruitingPhase 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RecruitingPhase 2
- Lenox Hill Brain Tumor Center, New York
FUS Etoposide for DMG
RecruitingPhase 1
- Columbia University Irving Medical Center, New York
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
RecruitingEarly phase 1
- NYU Langone Health, New York
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Recruiting
- Memorial Sloan Kettering Cancer Center, New York
Glioma trials in other cities
- Houston, TX23 studies
- Boston, MA20 studies
- Washington, DC19 studies
- Philadelphia, PA16 studies
- Columbus, OH15 studies
- Miami, FL15 studies
- San Francisco, CA14 studies
- Chicago, IL13 studies
- Durham, NC12 studies
- Seattle, WA11 studies
- St. Louis, MO10 studies
- Aurora, CO10 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.